Pfizer’s Talzenna in combination with Xtandi received the US FDA approval for mCRPC

Positive results from Merck’s Keytruda in Gastroesophageal Junction Adenocarcinoma

Seagen’s Brentuximab vedotin with modified chemo (BrECADD) regimen showed encouraging PFS in cHL

Promising results from BMS’s TRANSCEND clinical trials in FL and MCL presented at ICML 2023